The prequalification of the molecular test Xpert® MTB/RIF Ultra by the World Health Organization (WHO) marks a decisive breakthrough in the fight against tuberculosis (TB). This development promises to transform healthcare systems in low- and middle-income countries by providing rapid and accurate diagnostics that will improve early treatment and save lives, especially in vulnerable communities affected by this disease.
The prequalification process, led by the WHO, is a rigorous procedure that assesses whether a medical product, such as a diagnostic test, meets high international standards of quality, safety, and efficacy. This evaluation includes not only an analysis of the information provided by the manufacturer but also an independent review by accredited regulatory authorities, such as Singapore’s Health Sciences Authority in this case. By obtaining prequalification, the Xpert® MTB/RIF Ultra test ensures its suitability for use in public health programs worldwide, offering confidence to both healthcare providers and patients.
In Kenya, HIV infections are prevented with a ring
This test, designed for the GeneXpert® system, detects the genetic material of the Mycobacterium tuberculosis bacteria within hours, simultaneously identifying mutations that indicate resistance to rifampicin, a key drug. By facilitating early and reliable detection of TB and its multidrug-resistant variant, the Xpert® MTB/RIF Ultra empowers healthcare professionals with effective tools to contain and treat the disease more efficiently.
The positive impact of this breakthrough is immense. According to Dr. Yukiko Nakatani, WHO Assistant Director-General, the prequalification of this test ensures that countries can access high-quality diagnostic technologies, accelerating the response to one of the world’s deadliest infectious diseases. “This step reinforces our commitment to ensuring that the communities most affected by TB have access to innovative tools that can change lives,” she stated.
In addition to improving diagnostic accuracy, this achievement facilitates equitable access to advanced medical technologies, particularly in regions where healthcare systems face significant challenges. The prequalification of the Xpert® MTB/RIF Ultra test represents an innovative solution that will significantly reduce the global burden of tuberculosis while strengthening healthcare systems in high-need communities. This advancement paves the way for a more promising future, where early and precise diagnostics translate into effective treatments and a lasting positive impact in the fight against this devastating disease.
